The Pharma Closeout's EASD 2026 Debrief covers the readouts from the European Association for the Study of Diabetes meeting in Milan that matter for drug, device and payer strategy. The new ADA/EASD consensus report moves GLP-1 and SGLT2 drugs earlier in type 2 diabetes care, potentially from diagnosis, and prefers weight-lowering drugs for people with overweight or obesity. Lilly's ACHIEVE-4 put its oral GLP-1 pill Foundayo against insulin and met a heart-safety bar. Real-world data arrived from Novo on stepping up semaglutide versus switching, from Abbott on continuous glucose monitors, and from a Nordic study on semaglutide and pancreatic cancer. Plus the journal papers on retatrutide, survodutide and petrelintide, type 1 diabetes screening in children across Europe, and what to watch: Lilly and Novo results and ObesityWeek. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.
Auto-generated from the episode script. Deal names link to their scorecard in the database.
The final ADA and EASD consensus on type 2 diabetes makes drugs like Ozempic and Mounjaro, and the SGLT2 inhibitors, first-line considerations alongside metformin, and it wants weight-lowering drugs preferred for people with overweight or obesity.
And Lilly's pill orforglipron, approved for obesity as Foundayo, met a heart-safety bar against insulin, though proof of the heart benefit the consensus asks for is years away. The meeting showed how much evidence is arriving around the newer drugs in early diabetes care, and how carefully it has to be read.
Welcome to The Pharma Closeout EASD 2026 Debrief. I'm Alex Mercer.
And I'm Maya Patel. Our EASD 2026 Debrief brings you the readouts that matter, what they change, and what to watch next. The European Association for the Study of Diabetes met in Milan from September 28 to October 2, and its biggest document landed on the final day.
Our top story from EASD. On October 2nd, the ADA and EASD published their final consensus report on managing type 2 diabetes. It calls SGLT2 inhibitors and GLP-1-based therapy first-line therapeutic considerations, potentially from diagnosis, with a continuing role for metformin. Maya, the 2022 report already backed these drugs. Is that timing new?
What's new is "potentially from diagnosis", for most people. The 2022 report already said the cardiovascular benefits don't depend on metformin, and this one concedes that evidence comes from subgroups not protected by randomization. Weight changed too: it's now a central focus for everyone with type 2 diabetes, not just people with overweight or obesity, and for them weight-lowering drugs go from "considered" to "should be preferred".
Does the report say anything about cost, or does it leave that to payers?
It does, in a line carried over from 2022: where resources are tight, the highest-risk patients may need priority for the more expensive drugs. What 2026 adds is a counterweight, that affordability is improving as patents expire.
Our read: plans can cite both lines. One makes weight-lowering drugs the preferred choice for everyone with type 2 diabetes and overweight or obesity; the other lets a plan put the highest-risk patients first. The argument shifts from whether these drugs belong early to which patients get them soonest.
ACHIEVE-4 came after the report's search, which closed at the end of 2025, but bears on two of its steps: GLP-1 before insulin, and GLP-1-based therapy in heart disease. It was open-label: Lilly's pill Foundayo against titrated insulin glargine, in people already on up to three diabetes drugs, most with established heart disease.
On heart safety it cleared the bar, inside a wide margin of 1.8: the trial would have accepted up to 80 percent higher risk, and even the data's worst case was 20 percent higher. Lilly filed Foundayo for type 2 diabetes in the second quarter, and the report puts GLP-1-based therapy before insulin. If it's approved, that result is enough to compete for the pre-insulin slot, heart patients included.
Heart patients are where I'd disagree. For established cardiovascular disease, the report prefers a GLP-1-based therapy or an SGLT2 inhibitor with proven benefit, and a safety margin isn't proven benefit. Read against that wording, the heart-disease preference stays with agents that have it until Lilly's ATTAIN-OUTCOMES trial reads out, with primary completion estimated for 2031, and that slot is the one that matters.
The report's preference and the pre-insulin slot are different contests, and for the pre-insulin slot, as I see it, a heart-safety record against insulin is what counts. The filing doesn't rest on heart benefit: it rests on three pivotal ACHIEVE trials with superior A1C and weight results, and the report notes the drug needs no food or water restrictions and cut A1C and weight more than oral semaglutide at 7 to 14 milligrams.
Either way, the FDA decides first, and Lilly hasn't disclosed a date. Until then, the report's line stands: "currently only indicated for weight management".
Novo brought a real-world fight. In US claims data, people with type 2 diabetes who stepped up from 1 to 2 milligrams of semaglutide had about 6 percent fewer heart attacks, strokes and deaths from any cause than those who switched to Lilly's tirzepatide. Novo funded the analysis, and the percentage is its framing.
Novo's poster gives the absolute version: switching came with about one extra event for every 2,000 patients over a year.
On a slide, "six percent fewer events" sounds a lot bigger than that.
Most switchers stayed on lower tirzepatide doses, only about 31 percent reaching 10 milligrams or more, and there were about 23,000 of them against 186,000 who stepped up, with shorter follow-up and switching decisions claims data can't see. Novo and Lilly are contesting the same patient, someone on semaglutide who needs more, and this analysis is Novo's case for stepping up.
Next, glucose monitors. In US health records, adults with type 2 diabetes on basal insulin who started a continuous glucose monitor had 44 percent lower mortality at one year than matched non-users, per the EASD release; Abbott rounds it to 45. Most monitors in the study were Abbott's FreeStyle Libre, by its count.
Medicare's rule already covers continuous monitors for people on insulin, and for people with documented problematic hypoglycemia, so patients like the ones in this study already qualify. Does Abbott have anything on patients outside that rule?
Abbott points to French data that include that group: after people started its monitor, hospitalizations for acute diabetes events fell, most of all in those not on insulin. It's company-reported, with no confidence intervals, and it looks like a before-and-after comparison. Our read: that group, and who pays for its monitors, is the commercial question.
So the patients the payer question is about get the thinnest evidence, and the big number sits in the kind of patient Medicare's rule already covers. I'd discount that number on its merits too. In this Abbott-led study, deaths at one year of 1.16 percent against 2.09 make a 44 percent gap, more than a monitoring device plausibly delivers, a sign monitor users differed in ways the matching missed.
The study was observational, but set up to mirror a randomized trial: each monitor starter matched to a non-user on 29 characteristics, plus sensitivity checks that dropped the COVID period and deaths in the first 90 days.
The authors themselves say unmeasured confounding can't be excluded, and they didn't examine medication changes during follow-up.
The sensitivity checks still count for something, but you've moved me on the death figure: it can't carry a coverage case by itself. The hospitalization data are thinner, yet they include the kind of patient Medicare's rule leaves out, on an outcome a monitor can plausibly move, and that's where Abbott's coverage case will have to be built.
Another real-world readout, on safety this time. In Nordic registries, about 97,000 people with type 2 diabetes on semaglutide showed no detectable increase in pancreatic cancer risk against people on other diabetes drugs, per the EASD press release. Follow-up was short: under two years on average, after a one-year lag.
Novo funded it as a study regulators required. Its statistical range is wide, compatible with up to about 16 percent higher risk over the time observed, so a headline claiming semaglutide doesn't cause pancreatic cancer goes well past the data.
For Novo, the value is commercial and narrow: for semaglutide in type 2 diabetes only, it now has a regulator-mandated study to put in front of prescribers who raise pancreatic cancer. More after this.
If you find the show useful, subscribe to or share The Pharma Closeout on Spotify, Apple Podcasts, or wherever you listen. We appreciate you listening.
Over to obesity, where most of the news came as full journal papers on drugs we've already covered, and one newer name.
Retatrutide first, Lilly's investigational triple agonist. TRIUMPH-2 enrolled adults with obesity and type 2 diabetes, and last Sunday's Week in Review went through it dose by dose on the continued-treatment estimate, what would happen if everyone kept taking the drug. The Lancet paper leads with its primary analysis: at 80 weeks on the 12 milligram dose, the gap over placebo is 13.8 percentage points of body weight.
That analysis counts everyone randomized, whether or not they stayed on the drug, so a payer review will likely start there.
The paper also highlights side effects beyond the usual stomach ones. Dysesthesia, an abnormal skin sensation, reached 7.3 percent on the top dose against 0.7 on placebo, none severe or serious per the EASD release. Low blood pressure, including on standing, ran about 6 percent against under 1. Lilly says the program's data package supports filings in obesity, sleep apnea and knee osteoarthritis pain.
Type 2 diabetes isn't listed as an indication of its own. Lilly plans its application for US approval for the first quarter of 2027.
Boehringer's survodutide, an investigational glucagon and GLP-1 drug it licenses from Zealand, now has its SYNCHRONIZE-2 results in the New England Journal of Medicine: 76 weeks, in adults with type 2 diabetes and obesity.
The journal's analysis keeps people who stopped the drug in the count. On that basis, the higher dose came in just under 10 percent weight loss, against about 4 percent on placebo: a single trial's result, at its doses and duration, not a number to rank. Our October 1 show used the estimate that assumes people kept taking the drug.
Boehringer and Zealand's October 1 release adds a result from a different trial in the program, SYNCHRONIZE-1: in a small MRI substudy of people without type 2 diabetes, the weight came off preferentially from visceral and liver fat.
Did the release say how much of what they lost was muscle?
It puts muscle at no more than a tenth of tissue lost in that small substudy, and the consensus flags preserving muscle as an emerging consideration. Heart safety is the open question. SYNCHRONIZE-CVOT, about 5,500 people with overweight or obesity and heart disease, kidney disease or risk factors, reports later this year, Boehringer says. It tests first whether survodutide raises major cardiovascular events, then whether it lowers them.
The newer name is petrelintide, Zealand and Roche's investigational amylin drug, and the ZUPREME-1 Phase 2 trial, in people without type 2 diabetes, is now published in full. Its topline came out on March 5, and the next morning Zealand's shares fell about 32 percent in early trading. What did investors read into it?
BioSpace tied the fall to the size of the weight loss, below what investors expected. The market question since, as I read it, is whether petrelintide can stand apart from rival amylin programs, Lilly's among them.
Zealand's answer is tolerability, and its "placebo-like" line leaves out nausea: 20 percent on petrelintide against 6 percent on placebo.
Mostly mild and mostly during dose escalation, though, and only 1.5 percent stopped for stomach side effects, per the EASD release.
Nausea that's mild, early and rarely makes people stop is a smaller problem than I made it, so the tolerability pitch survives the paper. The open part is who it survives in, because the Phase 2 left out people with type 2 diabetes. Does the Phase 3 include them?
Zealand says it does: the ZUPREME Phase 3 program started on September 22 with three trials, about 7,000 people, covering overweight or obesity without type 2 diabetes, with type 2 diabetes, and with established heart disease. That sets Zealand and Roche against Lilly's amylin programs, in a field that also includes Novo's amylin-and-semaglutide combination, CagriSema.
Type 1 diabetes now. The EDENT1FI pilot programs screened 140,568 children across Europe for autoantibodies that mark early type 1. The pilots weren't population-representative, and the source is the EASD press release; we found no journal publication yet. Among children with an affected parent or sibling, about one child in 45 had early-stage disease.
How many of the children found were at a stage where an approved drug can delay the disease?
Only those at stage 2, where blood sugar is already abnormal: 18 percent of the 386 staged so far. Most, 78 percent, were at stage 1, autoantibodies with normal blood sugar, and the last 4 percent had already reached stage 3, clinical diabetes.
Sanofi's teplizumab is approved to delay stage 3 in children already at stage 2: in the US from age one, in the EU from age eight, and others are in development. Two of the study's authors disclose advisory ties to Sanofi. For any of those drugs, screening is how the stage 2 children get found.
Screening whom matters, though: children with an affected relative were only about 7 percent of those screened, and most of the children found had none. Screening has to go beyond families to find most cases.
Without an affected relative, the rate was about one in 350, so a program with limited tests starts with families.
For me, cases found is the measure that matters. Italy already has a law for nationwide type 1 screening, with implementation under way, and the authors recommend three testing windows through childhood and roll-out across Europe.
Three dates to watch. On October 29, Lilly reports third-quarter results. Listen for whether Lilly says anything about timing of the FDA's decision on Foundayo for type 2 diabetes, and for any type 2 diabetes filing plan for retatrutide.
A date there would tell us when the report's line that it's "currently only indicated for weight management" could stop being accurate.
On November 4, Novo reports nine-month results. Look for an update on CagriSema ahead of the US decision Novo expects in the fourth quarter. That matters to Zealand and Roche too, since CagriSema sits in the amylin field petrelintide has to stand out in.
November 14 to 17 brings ObesityWeek, in National Harbor, Maryland.
It's the next big venue for obesity data, and the first since the papers we've just covered.
What the meeting leaves us with: type 2 diabetes care moves earlier, with weight-lowering drugs preferred for people with overweight or obesity. ACHIEVE-4 tested the safety side of two of the report's steps, and the real-world readouts showed how far records studies can go. The obesity papers and the type 1 screening data add to the picture. We're glad you spent part of your day with us.
Follow the show on Apple Podcasts, Spotify, or wherever you listen — a quick rating or share helps other listeners find us. The daily briefing is back tomorrow morning.
The daily Closeout in under 15 minutes — trial readouts, FDA decisions, and the deal math behind them. Free.
Subscribe →